Bone metastases from renal cell carcinoma: 4 years after aggressive surgeries and anti‐angiogenic therapy

Abstract

Management of bone metastases from renal cell carcinoma (RCC) has significantly changed after the era of targeted therapy that improved the overall survival (OS). Surgical decision‐making remains a subject of controversy. We report a case of pelvic bone metastasis from RCC, 2 months after nephrectomy and surgery of a revealing clavicular metastasis.

Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma

“…It is surprising that there is limited information available on the effectiveness and safety of immunotherapy in patients with metastatic RCC who have bone metastases. While a few case reports have shown positive results in terms of radiological response in metastatic RCC patients treated with ICIs, there is still a need for more prospective data [76][77][78][79][80]. Nevertheless, reliable evidence on the efficacy of ICIs in bone metastases primarily comes from a subgroup analysis of the CheckMate 025 trial.…”

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

“…The integration of surgery with targeted therapy emerges as a strategic approach for achieving therapeutic effects, attaining local tumor control, and enhancing survival rate. [93] Furthermore, stereotactic body radiotherapy has also been proposed as a safe and effective treatment for patients with BOM-RCC harboring up to 5 lesions. Nonetheless, after 13 months of metastasis-directed localized therapy, a substantial fraction of these patients, nearly half, exhibit disease progression, particularly manifesting as distant metastasis beyond the initially treated sites.…”